1. Scrip
  2. >>Business
  3. >>Start-Ups & SMEs

Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies

 
• By Mike Ward

Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.

Euro currency
Abalos Secures Series A Funds For Immuno-Virotherapy Apporach

Effective treatment of advanced tumors remains a major challenge. Even though immunotherapies have shown significant benefit for some patients, limited recruitment of immune cells into tumors exposes the specific gaps of checkpoint blockade. Researchers led by Karl and Philipp Lang, from the universities of Duisburg-Essen and Duesseldorf, respectively, identifed a specific set of arenaviruses that preferentially infect and proliferate in tumor cells in a variety of murine and human cancer models. Essen-based start-up Abalos Therapeutics has been established to translate the work of the Lang teams and is pursuing an immune-virotherapy approach to bridge that gap.

Abalos is harnessing the unique immune stimulation of the arenavirus to develop a novel anti-cancer approach that provides the full breadth of the immune system’s power specifically against cancer cells

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Start-Ups & SMEs

More from Business

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.